Business Services Industry
Zacks Analyst Blog Highlights: Wet Seal, Inc., Freeport-McMoRan Copper & Gold, Inc., Johnson Controls, Inc., Syngenta AG and Monsanto Co
Business Wire, August 27, 2008
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Wet Seal, Inc. (Nasdaq: WTSLA), Freeport-McMoRan Copper & Gold, Inc. (NYSE: FCX), Johnson Controls, Inc. (NYSE: JCI), Syngenta AG (NYSE: SYT) and Monsanto Co. (NYSE: MON).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579
Here are highlights from Tuesday's Analyst Blog:
Wet Seal Weathering Storm
Wet Seal, Inc. (Nasdaq: WTSLA) reported solid results for the second quarter. The company's sales increased 4% year-over-year, and earnings increased 51%. The management also provided third-quarter guidance of sales between $145-$149 million and EPS of $0.05-$0.07. This compares to our previous estimates of $151 million and $0.05. We are lowering our estimates to reflect slower sales growth for the next few quarters.
That said, we expect the company to continue to benefit from cost controls, inventory management, and fewer store openings. However, those factors won't be enough to overcome the weaker sales trends. We maintain our Hold rating.
Freeport-McMoRan With Heft
Freeport-McMoRan Copper & Gold, Inc. (NYSE: FCX) reported second quarter EPS of $2.62, down 23.2% year-over-year, primarily due to lower sales volumes of copper and gold because of mine sequencing at the Grasberg mine in Indonesia.
Freeport-McMoRan was able to offset the increase in costs with the help of high copper and gold prices. The company has a strong cash flow position and several growth projects in its pipeline. The merger with Phelps Dodge Corporation has positioned FCX as the second-largest copper producer and the largest publicly traded copper company globally. We maintain our positive outlook and Buy rating on the stock. Our target price of $99.75 is based on around 8.9x our 2008 EPS estimate.
Johnson Controls Guidance Down
Johnson Controls, Inc.'s (NYSE: JCI) cost-reduction efforts, accretive acquisitions and healthy operating cash flows are driving the stock. Further, JCI commands a strong market share in its respective markets where it operates. The company has started benefiting from the York acquisition and will further benefit as it begins to integrate the Delphi Battery business.
The Delphi acquisition enables Johnson Controls to participate in the rapidly growing Asian automotive battery market. In the Power Solutions segment, JCI has received the three lithium-ion battery contracts available in the industry excluding Toyota. The company expects a lithium-ion battery ready for production by 2010 to be used in the gasoline electric hybrid vehicles.
Syngenta Poised for Growth
We remain buyers of Syngenta AG (NYSE: SYT) after the company's third quarter results. We retain our target price at $65 as re-rating continues. The depth of its product mix, robust business model and highly regarded management team support our positive view on the stock. We believe Syngenta is one of the safest plays on the sector, which should be reflected in higher valuations.
Syngenta is trading at 21.0x our 2008 EPS estimate. We think the discount to Monsanto Co. (NYSE: MON) is still unwarranted. We are aware of Monsanto's efforts and progress in Genetic Modified seeds versus Syngenta's, which have lagged, but a 70% premium valuation is still difficult to justify.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
- Emergence of “Femtomedicine” - New Frontier of Biomed Sciences - Reported at First Global Congress on Nano Medicine
- Research and Markets: Ethiopia Power Market Outlook to 2020
- Research and Markets: Orphan Drugs in Asia-Pacific: from Designation to Pricing, Funding & Market Access
- Research and Markets: Now You See It - TV Program Sponsorship & Product Placement in China
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FHM Features Anna Benson, Baseball's Hottest Wife
- Building a DNA database: the federal government has just enacted two bills related to DNA. The first would drive the collection of DNA from all infants. The second would attempt to prevent the DNA that is collected from being misused
- America's most wanted j-o-b-s - 10 hottest employment opportunities
- Developmental sequence in small groups


